Loading...
Chronic migraine — defined as 15 or more days of headache a month — can be challenging to treat even at tertiary headache centers. Researchers conducted a randomized, placebo-controlled, manufacturer-funded, phase III trial of galcanezumab in chronic migraine. After a run-in and baseline period, the 1113 participants were randomized to receive two 120-mg injections monthly of galcanezumab, one each of galcanezumab and placebo, or placebo only, for 3 months. Patients receiving onabotulinum toxin A for chronic migraine were excluded.
Both galcanezumab groups had a significantly greater reduction in mean monthly headache days than placebo at follow-up (120 mg galcanezumab, −4.8 days; 240 mg, −4.6; placebo, −2.7 days) and a significantly greater…